Innovators, Everywhere! LymeX Diagnostics Prize Attracts Over 50 Submissions
By Kristen Honey, PhD, PMP, Chief Data Scientist, Executive Director of InnovationX, Office of the Assistant Secretary for Health, HHS and Daniel Desautels, ORISE Fellow, OASH, HHS
Twitter: @HHSGov
The U.S. Department of Health and Human Services and the Steven & Alexandra Cohen Foundation (Cohen Foundation) announced that the LymeX Diagnostics Prize received 52 Phase 1 submissions. From May to August 2022, the first phase of this Lyme Innovation Accelerator competition called on experts to submit innovative detection methods that will advance Lyme disease diagnostics. Hailing from a range of organizations—including academia, innovation centers, major diagnostics corporations, and startup labs—entrants submitted a breadth of proposed solutions for detecting active Lyme disease infections in people. The ultimate goal of the multiphase competition is to nurture the development of diagnostics toward Food and Drug Administration review.
Although an estimated 476,000 Americans are diagnosed and treated for Lyme each year, there is no FDA-cleared test that can detect active infection. Early diagnosis of Lyme disease is critical: if left untreated, the debilitating disease can become harder to eradicate and can spread throughout the body. By using an open innovation structure, the LymeX Diagnostics Prize is able to offer funding alongside access to technical assistance while fostering collaboration opportunities—which provides incentives to a diverse group of experts to come together and address an unmet patient need. From adapting techniques such as radiology imaging, genomics sequencing, and microfluidics to translating approaches used in diagnosing other infectious diseases, including COVID-19, the concept papers that were submitted proposed a range of high-potential ideas.
It is a priority for this administration to protect and expand Americans’ access to quality, affordable health care. The success of Phase 1 of the LymeX Diagnostics Prize competition has the potential to address Americans’ critical need for an accurate Lyme disease diagnostic test. Phase 1 demonstrated that the competition’s open innovation model can accelerate scientific breakthroughs while fostering collaboration and partnerships.
A multidisciplinary group of technical reviewers and judges are evaluating submissions according to official Phase 1 evaluation criteria. Based on this evaluation, the judging panel will recommend up to 10 winners, who will each receive an equal share of the $1 million Phase 1 prize pool and an invitation to participate in a proposed Phase 2.
“We are thrilled by the wide range of solutions and look forward to working with the LymeX Diagnostics Prize’s community of collaborators to advance the next generation of Lyme disease diagnostics,” said Steven & Alexandra Cohen Foundation President Alexandra Cohen. “Through our $10 million pledge to the prize competition, we are committed to strengthening our public-private LymeX partnership with HHS.”
At the discretion of HHS and the Cohen Foundation, and subject to availability of future funding, at least one additional phase may follow Phase 2. Future phases are expected to focus on clinical and nonclinical validation of diagnostic tests that detect active infection by Lyme-disease-causing bacteria, as well as readiness for regulatory submission and market entry. Thanks to a $10 million pledge to the LymeX Diagnostics Prize from the Cohen Foundation, $9 million in additional LymeX prizes are projected to be available in proposed future phases.
To learn more, visit LymeXDiagnosticsPrize.com and subscribe to the competition newsletter.
About LymeX
The LymeX Diagnostics Prize is sponsored by the Lyme Innovation Accelerator, a partnership between the U.S. Department of Health and Human Services and the Steven & Alexandra Cohen Foundation. LymeX is the world’s largest public-private partnership for Lyme disease, fostering collaborative innovation among patients and advocates, academia, nonprofits, industry, and government. As a component of a larger moonshot, LymeX is identifying, developing, and implementing advancements in Lyme disease care. In addition to accelerating next-generation diagnostics, LymeX is spearheading development of human-centered solutions and fostering breakthroughs in education and awareness.
About the U.S. Department of Health and Human Services
HHS enhances and protects the health and well-being of all Americans. HHS fulfills that mission by providing for effective health and human services and by fostering sound, sustained advances in the sciences underlying medicine, public health, and social services.
About the Steven & Alexandra Cohen Foundation
The Steven & Alexandra Cohen Foundation is committed to inspiring philanthropy and community service by creating awareness, offering guidance, and leading by example to show the world what giving can do. The Foundation’s grants support nonprofit organizations based in the United States that either help people in need or solve complex problems. The Foundation is the largest private funder of Lyme and tick-borne disease research in the United States with over $75 million disbursed for groundbreaking studies in prevention, diagnostics, and treatment as well as building essential research infrastructure to catalyze innovation. The Foundation also spearheads grassroots campaigns to encourage others to give.
